CERS Cerus Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CERS

Price (delayed)

$2.93

Market cap

$587.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.05

Enterprise value

$655.96M

?
Relative Growth: Rel. Growth: 70
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 42

Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies ...

Highlights
CERS's EPS has surged by 50% year-on-year and by 38% since the previous quarter
The company's net income rose by 50% YoY and by 39% QoQ
The quick ratio has declined by 34% year-on-year and by 9% since the previous quarter
The gross margin has declined by 3.6% year-on-year and by 2.5% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.cerus.com
Peers: HAE BSX MLSS

Key stats

What are the main financial stats of CERS

CERS stock price

How has the Cerus stock price performed over time
Intraday
2.09%
1 week
-6.39%
1 month
10.98%
1 year
115.44%
YTD
42.23%
QTD
0.34%

Financial performance

How have Cerus's revenue and profit performed over time
Revenue
$244.84M
Gross profit
$143.04M
Operating income
-$3.18M
Net income
-$9.55M
Gross margin
58.4%
Net margin
-3.9%
Cerus's operating margin has surged by 78% YoY and by 65% QoQ
CERS's operating income has surged by 74% year-on-year and by 63% since the previous quarter
Cerus's net margin has surged by 58% YoY and by 42% QoQ
The company's net income rose by 50% YoY and by 39% QoQ

Price vs fundamentals

How does CERS's price correlate with its fundamentals

Growth

What is Cerus's growth rate over time

Valuation

What is Cerus stock price valuation
P/E
N/A
P/B
8.34
P/S
2.32
EV/EBIT
N/A
EV/EBITDA
213.53
EV/Sales
2.68
CERS's EPS has surged by 50% year-on-year and by 38% since the previous quarter
CERS's price to book (P/B) is 57% higher than its last 4 quarters average of 5.3 and 4.3% higher than its 5-year quarterly average of 8.0
CERS's equity is up by 22% year-on-year and by 5% since the previous quarter
The stock's price to sales (P/S) is 66% more than its last 4 quarters average of 1.4 but 20% less than its 5-year quarterly average of 2.9
CERS's revenue is up by 18% year-on-year and by 4.7% since the previous quarter

Efficiency

How efficient is Cerus business performance
CERS's return on sales has surged by 92% year-on-year and by 87% since the previous quarter
The ROIC has soared by 89% YoY and by 85% from the previous quarter
CERS's return on equity has surged by 56% year-on-year and by 42% since the previous quarter
Cerus's return on assets has surged by 55% YoY and by 40% QoQ

Dividends

What is CERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CERS.

Financial health

How did Cerus financials performed over time
CERS's total assets is 44% greater than its total liabilities
The quick ratio has declined by 34% year-on-year and by 9% since the previous quarter
Cerus's current ratio has decreased by 30% YoY and by 6% QoQ
Cerus's debt is 44% higher than its equity
CERS's equity is up by 22% year-on-year and by 5% since the previous quarter
Cerus's debt to equity has decreased by 20% YoY and by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.